{"id":"drug-lyc-30937-ec","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL3702597","moleculeType":"Small molecule","molecularWeight":"294.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It modulates the immune system by targeting specific immune cells, potentially leading to therapeutic effects in various diseases.","oneSentence":"LYC-30937-EC is an immunomodulatory drug.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:35:28.586Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT02872285","phase":"PHASE2","title":"An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Lycera Corp.","startDate":"2016-12-05","conditions":"Psoriasis","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Drug: LYC-30937-EC","genericName":"Drug: LYC-30937-EC","companyName":"Lycera Corp.","companyId":"lycera-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LYC-30937-EC is an immunomodulatory drug. Used for Treatment of autoimmune diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}